AstraZeneca made $10 billion offer for obesity drugmaker Rhythm, sources say
In short
AstraZeneca has approached the obesity drugmaker Rhythm with a buyout proposal valued at $10 billion. The potential transaction was disclosed by sources familiar with the matter, though further details regarding the status of the offer remain undisclosed. If advanced, the acquisition would grant AstraZeneca access to Rhythm's dedicated portfolio of obesity therapies.
Key points
- AstraZeneca is seeking to expand its footprint by bidding on a weight-loss drug developer.: AstraZeneca is seeking to expand its footprint by bidding on a weight-loss drug developer.
- The proposed transaction carries an estimated valuation of approximately $10 billion.: The proposed transaction carries an estimated valuation of approximately $10 billion.
- The outcome of the takeover bid remains uncertain as additional details have not been dis…: The outcome of the takeover bid remains uncertain as additional details have not been disclosed.